Obesity, especially morbid obesity - BMI greater than or equal to 40 kg/m² - has been identified as one of the main risk factors for the development of Type 2 Diabetes Mellitus (DM2). One of the treatment options for obesity and for DM2 is bariatric surgery. This is a cross-sectional, analytical and retrospective study based on medical records of patients undergoing bariatric surgery in a secondary hospital in Fortaleza, Ceará, from November 2018 to February 2021, evaluating the pre- and postoperative glycemic profile. In our study, after the inclusion and exclusion criteria, 18 patients were selected. All patients had significant postoperative weight loss during the evaluation period, with improved BMI, usually with a change in classification. Only one patient did not change the BMI classification, remaining morbidly obese and with low weight loss. In general, at the time before the surgical therapy, fifteen individuals were using some hypoglycemic therapy, of these, two were using insulin and oral hypoglycemic agents. In the follow-up, sixteen patients did not use any medication for glycemic control and 02 continued to use oral hypoglycemic agents, of which one patient was insulin dependent. A highly significant difference was observed between the use of pre- and postoperative medications, with p < 0.001.
